Shots: 

• Pfizer’s Emblaveo has received a positive CHMP opinion for the treatment of patients with cIAI, HAP (incl. VAP), and cUTI (incl. Pyelonephritis).  

• The MAA was supported by results from the P-III study comprising the REVISIT and ASSEMBLE studies evaluating the efficacy, safety, and tolerability of Emblaveo in treating serious bacterial infections due to Gram-negative bacteria (incl. MBL-producing multidrug-resistant pathogens for which there are limited or no treatment options) 

• AbbVie and Pfizer jointly developing Emblaveo, where Pfizer holds the global rights to commercialize Emblaveo outside of the U.S. and Canada and the development was also funded by US DoHHS. 

Ref: Pfizer | Image: Pfizer

Related News:- Pfizer Reports Results from P-III Trial of Abrysvo for Increased Risk for RSV Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com